Aberrant processing of plasma vitronectin and high-molecular-weight kininogen precedes the onset of preeclampsia

Reproductive Sciences

Volumn 16, Issue 12, 2009, Pages 1144-1152

  Blumenstein, Marion ^a   Prakash, Roneel ^b   Cooper, Garth J S ^a,c   North, Robyn A ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED   (New Zealand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Difference in gel electrophoresis; High molecular weight kininogen.; Plasma; Preeclampsia; Small for gestational age; Vitronectin

Indexed keywords

HIGH MOLECULAR WEIGHT KININOGEN; VITRONECTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; HUMAN; IMMUNOBLOTTING; NUCLEOTIDE SEQUENCE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; SMALL FOR DATE INFANT;

ADULT; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; LONGITUDINAL STUDIES; MOLECULAR WEIGHT; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PROTEIN PROCESSING, POST-TRANSLATIONAL; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY; VITRONECTIN;

EID: 70450173645     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719109342756     Document Type: Article

References (32)

1. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet. 2005 ; 365 (9461). 785-799.
2. Pijnenborg R., Anthony J., Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol. 1991 ; 98 (7). 648-655.
3. Redman CW, Sargent IL Latest advances in understanding preeclampsia. Science. 2005 ; 308 (5728). 1592-1594.
4. Bellamy L., Casas JP, Hingorani AD, Williams DJ Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007 ; 335 (7627). 974.
5. Heitner JC, Koy C., Kreutzer M., Gerber B., Reimer T., Glocker MO Differentiation of HELLP patients from healthy pregnant women by proteome analysis-on the way towards a clinical marker set. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 ; 840 (1). 10-19.
6. Watanabe H., Hamada H., Yamada N., et al. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics. 2004 ; 4 (2). 537-543.
7. Brown MA, Hague WM, Higgins J., et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol. 2000 ; 40 (2). 139-155. (Pubitemid 30323584)
8. Gardosi J., Mongelli M., Wilcox M., Chang A. An adjustable fetal weight standard. Ultrasound Obstet Gynecol. 1995 ; 6 (3). 168-174.
9. Benjamini Y., Hochberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Stat. 2000 ; 25 (1). 60-83.
10. Hardt M., Thomas LR, Dixon SE, et al. Toward defining the human parotid gland salivary proteome and peptidome: identification and characterization using 2D SDS-PAGE, ultrafiltration, HPLC, and mass spectrometry. Biochemistry. 2005 ; 44 (8). 2885-2899.
11. Campostrini N., Areces LB, Rappsilber J., et al. Spot overlapping in two-dimensional maps: a serious problem ignored for much too long. Proteomics. 2005 ; 5 (9). 2385-2395.
12. Colman RW Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des. 2006 ; 12 (21). 2599-2607.
13. Colman RW, Jameson BA, Lin Y., Johnson D., Mousa SA Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000 ; 95 (2). 543-550.
14. Schvartz I., Seger D., Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999 ; 31 (5). 539-544.
15. Chauhan AK, Moore TL. Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC). Clin Exp Immunol. 2006 ; 145 (3). 398-406.
16. Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thrombosis Res. 1998 ; 89 (1). 1-21.
17. Seiffert D., Schleef RR Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. Blood. 1996 ; 88 (2). 552-560.
18. Schroeck F., Arroyo de Prada N., Sperl S., Schmitt M., Viktor M. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn. Biol Chem. 2002 ; 383 (7-8). 1143-1149. (Pubitemid 35215061)
19. Conlan MG, Tomasini BR, Schultz RL, Mosher DF Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation. Blood. 1988 ; 72 (1). 185-190.
20. Tollefsen DM, Weigel CJ, Kabeer MH The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at arginine 379. J Biol Chem. 1990 ; 265 (17). 9778-9781.
21. Zhou Y., Fisher SJ, Janatpour M., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest. 1997 ; 99 (9). 2139-2151.
22. Xu P., Wang Y., Piao Y., et al. Effects of matrix proteins on the expression of matrix metalloproteinase-2, -9, and -14 and tissue inhibitors of metalloproteinases in human cytotrophoblast cells during the first trimester. Biol Reprod. 2001 ; 65 (1). 240-246.
23. Pijnenborg R., Luyten C., Vercruysse L., Van Assche FA Attachment and differentiation in vitro of trophoblast from normal and preeclamptic human placentas. Am J Obstet Gynecol. 1996 ; 175 (1). 30-36.
24. Stefansson S., McMahon GA, Petitclerc E., Lawrence DA Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des. 2003 ; 9 (19). 1545-1564.
25. Konstantinides S., SchCurrency signfer K., Loskutoff DJ. Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain. Arterioscler Thromb Vasc Biol. 2002 ; 22 (12). 1943-1945.
26. Stark JM Disequilibrium in control of proteolysis as a cause of pre-eclampsia. Lancet. 1978 ; 1 (8061). 417-419.
27. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1974 ; 19 (0). 331-358.
28. Wu Y., Rizzo V., Liu Y., Sainz IM, Schmuckler NG, Colman RW Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2007 ; 27 (9). 1968-1975.
29. Kleniewski J., Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992 ; 120 (1). 129-139.
30. Kleniewski J., Donaldson V. Granulocyte elastase cleaves human high molecular weight kininogen and destroys its clot-promoting activity. J Exp Med. 1988 ; 167 (6). 1895-1907.
31. Kozik A., Moore RB, Potempa J., Imamura T., Rapala-Kozik M., Travis J. A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J Biol Chem. 1998 ; 273 (50). 33224-33229.
32. Gupta AK, Gebhardt S., Hillermann R., Holzgreve W., Hahn S. Analysis of plasma elastase levels in early and late onset preeclampsia. Arch Gynecol Obstet. 2006 ; 273 (4). 239-242.